-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1765 Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Program: Oral and Poster Abstracts
Session: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Clinical Research, CML, Chronic Myeloid Malignancies, Diseases, Non-Biological therapies, Myeloid Malignancies, Study Population, Human
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Jorge E. Cortes, MD1, Delphine Rea2, Michael J. Mauro, MD3, Andreas Hochhaus, MD4, Dong-Wook Kim, MD, PhD5, Koji Sasaki, MD6, Fabian Lang7*, Michael C. Heinrich, MD8*, Massimo Breccia9*, Michael W. Deininger, MD, PhD10, Yeow Tee Goh, MD11, Jeroen J.W.M. Janssen12, Moshe Talpaz, MD13, Valle Gomez G De Soria, MD14*, Philipp le Coutre, MD15*, Francois-Xavier Mahon, MD, PhD16, Daniel Deangelo, MD, PhD17*, Shruti Kapoor, PhD18*, Gessami Sanchez-Olle19*, Meng Cao, PhD18*, Nithya Agrawal, MD18* and Timothy P Hughes, MD, MBBS, FRACP, FRCPA20

1Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA
2Department of Hématologie, Hôpital Saint-Louis, Paris, France
3Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York, NY
4Hematology/Oncology, Universitätsklinikum Jena, Jena, Germany
5Uijeongbu Eulji Medical Center, Uijeoungbu, Korea, Republic of (South)
6Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
7Department of Hematology/Oncology, Goethe University Hospital, Goethe University Hospital, Frankfurt/M, Germany
8Portland VA Health Care System and OHSU Department of Medicine, Division of Hematology and Oncology, Knight Cancer Institute, Portland, OR
9Department of Translational and Precision Medicine, Az., Hematology-Sapienza University, Rome, Italy
10Versiti Blood Research Institute, Milwaukee, WI
11Department of Haematology, Singapore General Hospital, Singapore, Singapore
12Radboud University Medical Center, Nijmegen, Netherlands
13Division of Hematology-Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI
14Hospital Universitario La Princesa, Madrid, Spain
15Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany
16Department of Hematology, Institut Bergonié, Bordeaux, Bordeaux, France
17Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
18Novartis Pharmaceuticals Corporation, East Hanover, NJ
19Novartis Pharma AG, Basel, Switzerland
20South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia

Background: T315I-mutated CML-CP is resistant to ATP-competitive tyrosine kinase inhibitors (TKIs), except ponatinib, which may be associated with safety concerns. A follow-up analysis of a phase 1 trial (NCT02081378) previously demonstrated durable efficacy and favorable safety of asciminib, the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket (STAMP), in patients with T315I-mutated CML-CP after ≥1 prior TKI. We provide final safety and efficacy data for patients with T315I-mutated CML-CP treated with asciminib monotherapy.

Methods: This analysis includes patients with T315I-mutated CML-CP after ≥1 prior TKI who received asciminib 200 mg twice daily (BID). Patients were enrolled between 2014 and 2020 (data cutoff: March 14, 2023).

Results: Forty-eight patients with T315I were included; 2 patients (4.2%) had additional baseline BCR::ABL1 mutations; 37 patients were male (median age 56.5 (range, 26-86) years. Forty patients (83.3%) had received ≥2 prior TKIs. At end of study, 25 patients (52.1%) continued asciminib therapy. Twenty-three patients discontinued treatment early, primarily due to lack of efficacy (11 [22.9%]) and adverse events (AEs; 4 [8.3%]).

Forty-five of 48 patients were evaluable for molecular response analysis; 3 were excluded for BCR::ABL1 atypical/e1a2/e1a3/unknown transcripts. No patients had major molecular response (MMR) at baseline. Nineteen of 45 evaluable patients (42.2%) achieved MMR of 53.3% by week 24, with rates increasing until week 264; 20 of 24 maintained or improved this response by the cutoff. Evaluable patients included 26 ponatinib-pretreated and 19 ponatinib-naive patients; 38.5% and 73.7%, respectively, achieved MMR by the data cutoff. The probability of maintaining MMR for ≥144 weeks was 86.0% (95% CI, 71.9-100.0). Of 45 evaluable patients, 31 (68.9%) achieved/maintained BCR::ABL1IS ≤1% and 14 (31.1%) and 12 (26.7%) achieved MR4 and MR4.5, respectively, by the data cutoff.

Median duration of exposure was 3.5 (range, 0.04-6.0) years; most patients (27 [56.3%]) received treatment for ≥2.8 years. The safety/tolerability profile of asciminib remained favorable after 1.4 years’ added exposure. Rates of any-grade (100.0%) and grade ≥3 (60.4%) AEs were consistent with rates at the January 6, 2021, cutoff. Most frequent (≥10%) grade ≥3 AEs included increased lipase (20.8%) and thrombocytopenia (14.6%). Two new patients had AEs leading to dose adjustment/interruption. No new AEs leading to discontinuation occurred. Two additional patients, both with baseline cardiovascular risk factors, experienced arterial occlusive events (AOEs; 6 [12.5%]). One experienced acute coronary syndrome and received continued access to asciminib; the other experienced cerebrovascular accident and myocardial infarction after discontinuation, while receiving continued access to asciminib, and died. This was the only study death reported in this patient population since the January 2021 cutoff.

Conclusions: Asciminib 200 mg BID exhibited clinical efficacy and sustained tolerability in patients with T315I-mutated CML-CP, a population with limited treatment options. After up to ≈6 years’ exposure, no new safety signals emerged, and efficacy was sustained with durable MMR achieved in 53% of patients. Asciminib remains an excellent treatment option for patients with T315I-mutated CML-CP, including those with prior ponatinib treatment.

Disclosures: Cortes: Novartis: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Sun Pharma: Consultancy, Research Funding; Rigel: Consultancy; Nerviano: Consultancy; Takeda: Consultancy; Biopath Holdings: Consultancy, Research Funding; Abbvie: Research Funding. Rea: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees. Mauro: Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria; Sun Pharma/SPARC: Research Funding. Hochhaus: Novartis: Honoraria, Other: Advisory Board, Research Funding; Terns: Honoraria, Other: Advisory Board; Enliven: Honoraria, Other: Advisory Board. Kim: Il-Yang: Honoraria, Research Funding, Speakers Bureau; Pharmaessencia: Research Funding; Korea Otsuka: Honoraria, Research Funding, Speakers Bureau; Enliven: Honoraria, Research Funding; Novartis: Honoraria, Research Funding, Speakers Bureau; BMS: Honoraria, Research Funding, Speakers Bureau. Sasaki: Enliven: Research Funding; Chugai: Other: Lecture fees; Novartis: Consultancy, Research Funding; Otsuka: Other: Lecture fees; Daiichi-Sankyo: Consultancy; Pfizer: Consultancy. Lang: Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Heinrich: Novartis: Consultancy; Theseus: Consultancy; Deciphera: Consultancy; Cstone Pharmaceuticals: Consultancy; Zai Labs: Consultancy. Breccia: AOP: Honoraria; BMS: Honoraria; Abbvie: Honoraria; Pfizer: Honoraria; Incyte: Honoraria; Novartis: Honoraria; GSK: Honoraria. Deininger: Leukemia & Lymphoma Society: Research Funding; SPARC: Research Funding; Fusion Pharma: Consultancy; DisperSol: Consultancy; Takeda: Honoraria, Other: Part of a study management committee, Research Funding; Sangamo: Consultancy, Honoraria; Medscape: Honoraria, Other: Case Author ; Incyte: Honoraria, Research Funding; Blueprint Medicines Corporation: Consultancy, Honoraria, Other: Part of a study management committee, Research Funding; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Grants, Travel, , Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Grants, travel, clinical trial support, Research Funding. Goh: Novartis: Consultancy; AstraZeneca: Consultancy; Johnson & Johnson: Consultancy, Honoraria; Antengene: Consultancy; Amgen: Consultancy; EUSA Pharma: Consultancy; Pfizer: Consultancy; MSD: Honoraria; Roche: Honoraria; Astellas: Honoraria; AbbVie: Honoraria; NS Pharma: Consultancy. Janssen: Abbvie: Other: Advisory Board; BMS: Research Funding; Novartis: Other: Advisory Board, Research Funding. Talpaz: BMS: Membership on an entity's Board of Directors or advisory committees, Research Funding; Imago: Membership on an entity's Board of Directors or advisory committees; Arcus: Research Funding; KyowaKirin: Membership on an entity's Board of Directors or advisory committees; Sumitomo: Membership on an entity's Board of Directors or advisory committees; SierraOncology: Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees. le Coutre: AOP: Honoraria; BMS: Honoraria; Pfizer: Honoraria; Blueprint: Honoraria; Incyte: Honoraria; Novartis: Honoraria. Mahon: Novartis: Consultancy, Honoraria, Other: Grants, Research Funding; BMS: Honoraria; Pfizer: Honoraria. Deangelo: Glycomimetics: Research Funding; Abbvie: Research Funding; Forty-seven: Consultancy; Blueprint: Consultancy, Research Funding; Amgen: Consultancy; Agios: Consultancy; Autolos: Consultancy; Takeda: Consultancy; servier: Consultancy; Pfizer: Consultancy; Novartis: Consultancy, Research Funding; Jazz: Consultancy; incyte: Consultancy; Gilead: Consultancy. Kapoor: Novartis: Current Employment. Sanchez-Olle: Novartis: Current Employment. Cao: Novartis: Current Employment. Agrawal: Novartis: Current Employment. Hughes: Ariad: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Novartis: Consultancy, Honoraria, Research Funding.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH